# Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Can

Source: https://onco.cc/trials/nct06704620/  
OnCo record `nct06704620` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of tislelizumab, pemetrexed, carboplatin and cisplatin in lung cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.

## Summary

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT06704620 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 430 participants, started 2024-12 and due to reach its primary completion in 2026-11. Interventions recorded: Diphenhydramine; Tislelizumab; Pemetrexed; Albumin paclitaxel; Carboplatin; Cisplatin. Conditions listed: Advanced and Metastatic NSCLC. Primary outcome: PFS. Lung eligibility wording from the registry: "Patients diagnosed with stage IIIB-IV NSCLC by imaging, tissue and/or cytology (according to AJCC 9th edition), or primary stage IIIB-IV NSCLC that relapses after surgery (if adjuvant therapy has been used, the drug must be discontinued for more than 6 months);Patients with IIIB/C are unable to unde". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06704620
- Phase: 3
- Setting: Safety and Effectiveness of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer: A Prospective, Randomized-controlled, Multi-center, Open-label, Phase-III Trial.
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 430

## Sources

- ClinicalTrials.gov NCT06704620: https://clinicaltrials.gov/study/NCT06704620

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06704620.json